PL
Havana, Aug 31 (RHC)--Cuba and Mexico announced the creation of the joint venture IncuBio in the Mariel Special Development Zone to attract capital and finance proof-of-concept clinical trials in developed country markets.
The Caribbean island was represented by Cimab S.A. and the foreign party Neuronic Mexicana S.A. de C.V., in the new entity with an exclusive license for developing and commercializing innovative biotechnological products, including NeuroEPO, the former said on its Twitter account.
Considered one of the most promising assets in the Center for Molecular Immunology (CIM) portfolio, a leading Cuban biotechnology company, NeuroEPO is an intranasal formulation of recombinant human erythropoietin with a low sialic acid content, currently under clinical evaluation.
The latter studies the treatment of several neurodegenerative diseases such as Parkinson's and Ataxia, which, during the proof-of-concept trial recently completed in Cuba, showed evidence of acting as a homeostatic regulator of the brain and improvement of cognitive impairment in Alzheimer's patients.
Cimab S.A. is dedicated to business development and management through its direct participation in international alliances involving CIM's main biotechnological products.
According to the publication, with the incorporation of IncuBIO, the company is a shareholder of five joint ventures located in China, Thailand, Singapore, and Mexico.
Neuronic Mexicana S.A. de C.V. was incorporated in 1996 and is dedicated to the commercialization of biopharmaceutical products and medical equipment.
